ClinVar Miner

Submissions for variant NM_000263.4(NAGLU):c.1811C>T (p.Pro604Leu)

gnomAD frequency: 0.00002  dbSNP: rs751203469
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000670027 SCV000794837 likely pathogenic Mucopolysaccharidosis, MPS-III-B 2017-10-17 criteria provided, single submitter clinical testing
Baylor Genetics RCV000670027 SCV001523048 pathogenic Mucopolysaccharidosis, MPS-III-B 2019-12-06 criteria provided, single submitter clinical testing This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].
CeGaT Center for Human Genetics Tuebingen RCV001532304 SCV001747800 pathogenic not provided 2021-03-01 criteria provided, single submitter clinical testing
Invitae RCV001855534 SCV002288719 likely pathogenic Mucopolysaccharidosis, MPS-III-B; Charcot-Marie-Tooth disease axonal type 2V 2023-10-13 criteria provided, single submitter clinical testing This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 604 of the NAGLU protein (p.Pro604Leu). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with mucopolysaccharidosis type III (PMID: 21910976, 23100014). ClinVar contains an entry for this variant (Variation ID: 554402). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt NAGLU protein function. Experimental studies have shown that this missense change affects NAGLU function (PMID: 29979746). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
GeneDx RCV001532304 SCV002546618 pathogenic not provided 2022-07-08 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect on enzyme activity (Clark et al., 2018); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 22908982, 23100014, 21910976, 29979746)
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000670027 SCV002572315 pathogenic Mucopolysaccharidosis, MPS-III-B 2022-08-25 criteria provided, single submitter clinical testing Variant summary: NAGLU c.1811C>T (p.Pro604Leu) results in a non-conservative amino acid change located in the Alpha-N-acetylglucosaminidase, C-terminal domain (IPR024732) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.3e-05 in 227262 control chromosomes (gnomAD). c.1811C>T has been reported in the literature in individuals affected with Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome B) (examples: Ouesleti_2011 and Klaas_2013 ). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity (example: Clark_2018). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Institute of Human Genetics, University Hospital Muenster RCV000670027 SCV002578010 likely pathogenic Mucopolysaccharidosis, MPS-III-B 2022-08-19 criteria provided, single submitter clinical testing ACMG categories: PM1,PM2,PP3,PP5

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.